Clinical trial registry record

Study to Assess Best Corrected Visual Acuity (BCVA) in Patients With Neovascular Age-Related Macular Degeneration (AMD) Who Are Administered VEGF Trap-Eye (Intravitreal Aflibercept Injection)

A registered PHASE4 study indexed because it matched monitored longevity research terms. Registry status: Completed. Registration does not establish safety or effectiveness.

Plain-language guide

Five questions to ask about this record

What this is
A clinical study registration, not a result or recommendation.
Why it may matter
The registry currently reports Completed.
Evidence
Registered phase 4 study.
Main limitation
Registration does not prove that the intervention works, is safe, or is available to you.
What changed
Registry metadata was last updated December 22, 2017.
Where to verify
Open the primary registry below for eligibility, locations, contacts, and current status.
Registry ID
NCT01722045
Last registry update
December 22, 2017
Status
Completed
Phase
Phase 4
Sponsor
Regeneron Pharmaceuticals
Enrollment
154
Countries
United States
Match confidence
80%
Source feed
ClinicalTrials.gov
Automated source synopsis

A registered PHASE4 study indexed because it matched monitored longevity research terms. Registry status: Completed. Registration does not establish safety or effectiveness.

Evidence snapshot

What the source actually supports

Evidence stage
Phase 4
Study design
NA · SINGLE GROUP · TREATMENT · NONE
Evidence population
Human clinical study registration
Participants
154
Population
ALL · 50 Years
Duration
2012-11-01 to 2015-09-01
Intervention
Intravitreal Aflibercept Injection (IAI)
Comparator
Not reported
Outcomes measured
Change in Early Treatment Diabetic Retinopathy Study (ETDRS) Letter Score From Baseline to Week 100 - Last Observation…; Percentage of Participants Whose Optical Coherence Tomography (OCT) Status Was "Dry" at Week 52 and at Week 100 (LOCF)…; Percentage of Participants Who Gained ≥15 ETDRS Letters Compared With Baseline at Week 52 and Week 100 (LOCF) — At week…; Change From Baseline in Best Corrected Visual Acuity Score Through Week 52 (LOCF) — Baseline to Week 52; Percentage of Participants Who Gained ≥0, ≥5, ≥10, or ≥30 Letters From Baseline in BCVA Through Week 100 (LOCF) — Basel…; Percentage of Patients Who Lost >0, ≥5, ≥10, or ≥15 Letters From Baseline in BCVA Through Week 100 (LOCF) — Baseline to…
Reported result
No reusable finding-level result is available in this record.

Main limitationThis is a study registration. No reusable structured result is available here, so it cannot show whether the intervention worked or was safe.

Safety and approvalEligibility, adverse-event details, and clinical decisions must be checked in the official registry and with qualified clinicians. Trial registration is not regulatory approval and does not establish that an intervention is available.

Source supportStructured registry protocol metadata; no finding-level conclusion is generated.

Trial stage · Phase 4A trial phase describes development stage; it does not establish a positive result.
Phase 1Phase 2Phase 3Phase 4

Registration and recruitment status do not establish safety, efficacy, or regulatory approval.

Why this record appears here · 80% topic match

The title, summary, or source keywords matched one or more topics followed by immortal.life. A higher percentage means a stronger topic match; it does not rate safety, effectiveness, or study quality.

  • Vision ageing · 80%Title contains controlled topic terminology. Title supplies ageing or longevity context.

Automated source check 100% · update recency 50%. These figures help sort records; they are not medical ratings.

vision aging
Read the original source →Export JSON